Navigation Links
China Health Resource, Inc. Defers Implementation of Reverse Stock Split in Light of Continuing Market Volatility
Date:4/9/2009

SUINING CITY, Sichuan Province, P.R. China, April 9, /PRNewswire-FirstCall/ -- China Health Resource, Inc. (OTC Bulletin Board: CHRI), a Delaware corporation, announced today that its Board of Directors (the "Board") has decided to defer immediate implementation of a reverse stock split of the Company's Class A common stock at this time in light of the continuing volatility in the global capital markets. The Board considers that the current market instability would undermine the purpose and intent of the action. The Company and the Board will continue to monitor and analyze market conditions, as well as other strategic opportunities that may become available to the Company in order to achieve its financial objectives and to increase shareholder value. The Board has reserved the discretion to implement the reverse stock split at a future date or not at all.

On February 17, 2009, in accordance with Delaware corporate law, the holders of a majority of the outstanding shares of our common stock executed a written consent approving a number of proposals, including the reverse stock split, which consent became effective on April 4, 2009. An Information Statement, dated March 12, 2009 was filed with the SEC and provided to shareholders describing the various proposals subject to the stockholder consent. These proposals included (i) election of members of the Board of Directors; (ii) ratification of the Company's auditors for fiscal year 2009; (iii) certain amendments to the Company's Certification of Incorporation to, among other things, reduce the par value of the Class A common stock, eliminate the Class B common stock, and provide for blank check preferred stock; and (iv) adoption of a stock option incentive plan for directors, officers, employees and consultants of the Company. The amendments to the Company's Certification of Incorporation will become effective upon the applicable filing with the Secretary of the State of Delaware. A copy of the definitive Information Statement may be obtained from the SEC's website at www.sec.gov or the Company's website at www.chriglobal.com.

About China Health Resource

China Health Resource engages in the development and commercialization of the Dahurian Angelica Root ("DAR"), a popular traditional Chinese medicine, in the People's Republic of China. DAR is a popular herb employed extensively as an ingredient in food, medicine, and cosmetics and is used for the treatment of pain, swelling, and pustule. In addition, the Company sells DAR-related products, which include the Bai Ling Capsule, Yi Shen Capsule, DAR slices, and DAR scent bag through regional distributors throughout the People's Republic of China. For more information, visit http://www.chriglobal.com/.

Safe Harbor and Forward-Looking Statements

Certain statements found in this document, including statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These forward-looking statements include statements of management's plans and objectives for our future operations. Actual results and developments could differ materially from those expressed in or implied by such statements due to a number of factors, including, without limitation, those described in the context of such forward-looking statement, our expansion and acquisition strategy, our ability to achieve operating efficiencies, our dependence on network infrastructure, capacity, telecommunications carriers and other suppliers, industry pricing and technology trends, evolving industry standards, domestic and international regulatory matters, general economic and business conditions, the strength and financial resources of our competitors, our ability to find and retain skilled personnel, the political and economic climate in which we conduct operations and the risk factors described from time to time in our other documents and reports filed with the SEC. Additional factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to: (1) our ability to successfully develop, manufacture and deliver DAR and related products on a timely basis and in the prescribed condition; (2) our ability to compete effectively with other companies in the same industry; (3) our ability to raise sufficient capital in order to effectuate our business plan; and (4) our ability to retain our key executives. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission, including our reports on Forms 10-K, 10-KSB, and 10-Q and the foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE China Health Resource, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
Breaking Medicine Technology: